Antineoplastics
1
Reactions 1514, p10 - 16 Aug 2014 ★ Antineoplastics First report of lipomatosis: case report A 28-year-old man who received chemotherapy developed multiple lipomatosis [routes, dosages and time to reaction onset not stated]. The man presented with multiple soft subcutaneous lesions, clinically consistent with lipomas, which had recently increased in size and were unpleasant and annoying. He had been diagnosed with testicular cancer in 2009, and had received three cycles of chemotherapy with cisplatin, etoposide and bleomycin (PEB); he had achieved a partial remission. He had subsequently received stem cell chemomobilisation with carboplatin, etoposide and granulocyte colony-stimulating factor (G-CSF), followed by three cycles of paclitaxel, ifosfamide and cisplatin (TIP), before undergoing stem cell transplantation. Chemotherapy had been completed in 2010, and his lipomas had developed in 2011. The man underwent surgery to remove 32 encapsulated lipomas; histology was compatible with angiolipoma. No recurrence occurred during follow-up. Author comment: "Although a clear aetiology has never been defined, in our case three possible causes have been hypothesized: stem cell mobilization or transplant and chemotherapy." "Despite an unknown underlying mechanism, the cisplatin-based chemotherapy may appear the major contributor." Bracaglia R, et al. Multiple lipomatosis after stem cell transplant and chemotherapy: A case report. European Review for Medical and Pharmacological Sciences 18: 413-415, No. 3, 2014 - Italy 803106904 » Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of lipomatosis associated with cisplatin, etoposide, bleomycin, carboplatin, G-CSF, paclitaxel or ifosfamide. The WHO ADR database did not contain any reports of lipomatosis associated with cisplatin, etoposide, bleomycin, carboplatin, G-CSF, paclitaxel or ifosfamide. 1 Reactions 16 Aug 2014 No. 1514 0114-9954/14/1514-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1514, p10 - 16 Aug 2014
★Antineoplastics
First report of lipomatosis: case reportA 28-year-old man who received chemotherapy developed
multiple lipomatosis [routes, dosages and time to reactiononset not stated].
The man presented with multiple soft subcutaneous lesions,clinically consistent with lipomas, which had recentlyincreased in size and were unpleasant and annoying. He hadbeen diagnosed with testicular cancer in 2009, and hadreceived three cycles of chemotherapy with cisplatin,etoposide and bleomycin (PEB); he had achieved a partialremission. He had subsequently received stem cellchemomobilisation with carboplatin, etoposide andgranulocyte colony-stimulating factor (G-CSF), followed bythree cycles of paclitaxel, ifosfamide and cisplatin (TIP), beforeundergoing stem cell transplantation. Chemotherapy had beencompleted in 2010, and his lipomas had developed in 2011.
The man underwent surgery to remove 32 encapsulatedlipomas; histology was compatible with angiolipoma. Norecurrence occurred during follow-up.
Author comment: "Although a clear aetiology has neverbeen defined, in our case three possible causes have beenhypothesized: stem cell mobilization or transplant andchemotherapy." "Despite an unknown underlying mechanism,the cisplatin-based chemotherapy may appear the majorcontributor."Bracaglia R, et al. Multiple lipomatosis after stem cell transplant andchemotherapy: A case report. European Review for Medical and PharmacologicalSciences 18: 413-415, No. 3, 2014 - Italy 803106904
» Editorial comment: A search of AdisBase, Medline andEmbase did not reveal any previous case reports of lipomatosisassociated with cisplatin, etoposide, bleomycin, carboplatin,G-CSF, paclitaxel or ifosfamide. The WHO ADR database did notcontain any reports of lipomatosis associated with cisplatin,etoposide, bleomycin, carboplatin, G-CSF, paclitaxel orifosfamide.
1
Reactions 16 Aug 2014 No. 15140114-9954/14/1514-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
